Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives
Age
18–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Male or female patients (using effective contraception and a negative pregnancy test for women of childbearing age) diagnosed with UC for at least 3 months
Age ≥ 18 years and ≤ 65 years
Moderate to severe UC according to modified Mayo score (from 5 to 9)
With endoscopic Mayo score ≥ 2
With an inadequate response, failure, loss of response, or intolerance to 5-ASA, steroids, or immunosuppressants.
Patient capable of giving consent
Patient covered by the French healthcare system
Women of childbearing age using active contraception (contraceptive implant, oral contraception, female condom or abstinence)) for at least the duration of the study
You may not be if
Usual contra-indication to infliximab, filgotinib, vedolizumab or ustekinumab
Steroids \> 20 mg/day within two weeks before inclusion
Low proctitis (disease limited to the rectum with an extent \< 5 cm)
Prior history of thromboembolism events
Prior history of major cardiovascular problems (such as heart attack or stroke)
Long-standing smokers (\> 40 pack years)
Crohn's disease
Stoma or colectomy
Prior exposure to anti-TNF agents, anti-integrins, anti-interleukines 12 and 23 or JAK inhibitor
Prior exposure to other biologics or experimental drug
No health insurance
Pregnant or lactating women : a pregnancy test will be performed for women of childbearing age
Patients already included in biomedical research other than an observational study (e.g: registry, cohort)
Concomitant Clostridioides difficile infection
HIV infection
Patient who does not master the French language
Patient under guardianship, curatorship or safeguard of justice
Minors
Clareo Health | FirST Lines of Biologics in pAtients With ulceRaTivE Colitis: a Randomised Controlled Trial
